Get the Stockscreener App
12.30
5.76%
0.67
After Hours:
12.18
-0.12
-0.98%
Wave Life Sciences Ltd stock is traded at $12.30, with a volume of 3.58M.
It is up +5.76% in the last 24 hours and down -15.41% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$11.63
Open:
$12.18
24h Volume:
3.58M
Relative Volume:
1.11
Market Cap:
$2.32B
Revenue:
$42.73M
Net Income/Loss:
$-204.38M
P/E Ratio:
-10.15
EPS:
-1.2124
Net Cash Flow:
$-189.73M
1W Performance:
+3.36%
1M Performance:
-15.41%
6M Performance:
+84.68%
1Y Performance:
+30.30%
1-Day Range:
$12.01
$12.67
1-Week Range:
$11.13
$12.67
52-Week Range:
$5.28
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
12.30 | 2.19B | 42.73M | -204.38M | -189.73M | -1.2124 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | BofA Securities | Buy |
| Dec-12-25 | Reiterated | Wedbush | Outperform |
| Dec-09-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Jefferies reiterates Buy on Wave Life Sciences stock ahead of May data - Investing.com
Guidance Update: Can Wave Life Sciences Ltd beat the S P 5002026 AllTime Highs & Expert Verified Movement Alerts - baoquankhu1.vn
WVE: Mizuho Maintains Outperform, Raises Price Target to $27 | W - GuruFocus
WAVE Life Sciences (NASDAQ:WVE) Price Target Raised to $27.00 at Mizuho - MarketBeat
Here’s What Boosted Wave Life Sciences Ltd. (WVE) in Q4 - Insider Monkey
Mizuho raises Wave Life Sciences stock price target on obesity drug progress - Investing.com UK
Avoiding Lag: Real-Time Signals in (WVE) Movement - Stock Traders Daily
Traders Purchase Large Volume of WAVE Life Sciences Put Options (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Hits Day Low of $13.59 Amid Price Pressure - Markets Mojo
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2025 earnings call transcript - MSN
Quarterly Trades: Does Wave Life Sciences Ltd stock have upside surprise potential2026 Macro Moves & Weekly Return Optimization Plans - baoquankhu1.vn
WVE Stock Price, Quote & Chart | WAVE LIFE SCIENCES LTD (NASDAQ:WVE) - ChartMill
Wave Life Sciences reports positive early data from obesity drug trial - MSN
WVE Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
WAVE Life Sciences teams prepare to share development insights at OPTBoston - Traders Union
BofA highlights WVE-007 as primary driver for Wave Life Sciences Ltd. (WVE)’s growth, projecting peak sales above $11B - MSN
Cinctive Capital Management LP Lowers Holdings in WAVE Life Sciences Ltd. $WVE - MarketBeat
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF) - The Globe and Mail
Assessing Wave Life Sciences (WVE) Valuation After WVE-007 Obesity Data And Cash Runway Update - simplywall.st
WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Discipline and Rules-Based Execution in WVE Response - Stock Traders Daily
Dynamic SXSW panel reshapes obesity treatment narrative, WAVE Life Sciences asserts - Traders Union
Canaccord Genuity Boosts Price Target for WAVE Life Sciences (WV - GuruFocus
WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) - Benzinga
WAVE Life Sciences (NASDAQ:WVE) Given New $52.00 Price Target at Canaccord Genuity Group - MarketBeat
Wave Life Sciences (WVE) soars to 6-year high on obesity drug clinical trial - MSN
Wave Life Sciences to present WVE-006 trial data at ATS - Investing.com Nigeria
Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval PushWhat's Changed - simplywall.st
Wave Life Sciences Bets on Data Over Near-Term Revenue - TipRanks
WVE: Wedbush Raises Price Target for WAVE Life Sciences, Reaffir - GuruFocus
Wave Life Sciences (WVE) Valuation Check After New RNA Editing And Obesity Trial Updates - simplywall.st
Wedbush Forecasts Strong Price Appreciation for WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat
Wave Life Sciences (WVE) Anticipates Positive Developments with WVE-007 Data - GuruFocus
Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Sahm
Wave Life Sciences to present WVE-006 trial data at ATS By Investing.com - Investing.com Canada
Wave Life Sciences announces acceptance of late-breaking oral presentation on Wve-006 for alpha-1 antitrypsin deficiency at the American Thoracic Society international conference - marketscreener.com
Wave Life Sciences Announces Acceptance of Late-Breaking - GlobeNewswire
Q1 EPS Forecast for WAVE Life Sciences Raised by Analyst - MarketBeat
FY2029 Earnings Forecast for WVE Issued By HC Wainwright - MarketBeat
Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside - simplywall.st
WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan
Wave Life Sciences Ltd. (WVE) Stock Analysis: Biotechnology Innovator with 140% Upside Potential - DirectorsTalk Interviews
How Strong Q4 Revenue Amid Deeper Losses At Wave Life Sciences (WVE) Has Changed Its Investment Story - Yahoo Finance
Wave Life Sciences (WVE) Earnings Call Transcript - AOL.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2025 Earnings Call Transcript - Insider Monkey
HC Wainwright Reiterates "Buy" Rating for WAVE Life Sciences (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Teases Near-Term Obesity and RNA Editing Data as INLIGHT Readouts Near - Yahoo Finance
Artisan Partners Limited Partnership Trims Stake in WAVE Life Sciences Ltd. $WVE - MarketBeat
How Mixed Q4 Results, Obesity Data and Cash Runway News At Wave Life Sciences (WVE) Has Changed Its Investment Story - simplywall.st
Wave Life Sciences Ltd. (WVE): A Bull Case Theory - Finviz
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):